Sign in
4

Changes in Ownership

Kiniksa Pharmaceuticals International, plc Filed Acc 0001464583-26-000008

CHIEF ACCOUNTING OFFICER sold 4,600 shares at $80.30 ($369,380)

  • CHIEF ACCOUNTING OFFICER gave up 5,531 shares (to pay taxes)
  • CHIEF ACCOUNTING OFFICER acquired 279 shares (grant or award)
  • CHIEF ACCOUNTING OFFICER acquired 11,496 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Megna Michael R · CHIEF ACCOUNTING OFFICER

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2026-07-15 Grant or award : show line 1 in the form 10b5-1 +279 $33.50 $9,347 27,697 D
2026-09-01 Exercise or conversion : show line 2 in the form 10b5-1 +3,932 31,629 D
2026-09-01 Exercise or conversion : show line 3 in the form 10b5-1 +2,558 34,187 D
2026-09-01 Exercise or conversion : show line 4 in the form 10b5-1 +2,362 36,549 D
2026-09-01 Exercise or conversion : show line 5 in the form 10b5-1 +2,644 39,193 D
2026-09-01 Shares withheld for taxes : show line 6 in the form 10b5-1 −5,531 $79.28 $438,498 33,662 D
2026-09-03 Sale : show line 7 in the form 10b5-1 −4,600 $80.30 $369,380 29,062 D
Open-market sales · 4,600 sh · avg $80.30 · $369,380

Table II: Derivative

6 lines
Date Transaction Shares Owned after D/I
2026-09-01 Grant or award : show line 8 in the form 10b5-1 Restricted Share Unit +3,650 3,650 D
2026-09-01 Grant or award : show line 9 in the form 10b5-1 Share Option +14,600 14,600 D
2026-09-01 Exercise or conversion : show line 10 in the form 10b5-1 Restricted Share Unit −2,644 7,931 D
2026-09-01 Exercise or conversion : show line 11 in the form 10b5-1 Restricted Share Unit −2,362 4,725 D
2026-09-01 Exercise or conversion : show line 12 in the form 10b5-1 Restricted Share Unit −2,558 2,557 D
2026-09-01 Exercise or conversion : show line 13 in the form 10b5-1 Restricted Share Unit −3,932 0 D
Loading xslF345X06/form4-09032026_080913.xml…